Real-World Outcomes of First-Line Ribociclib Plus Aromatase Inhibitor in Patients With HR+/HER2− MBC

[Hazelgreen]

Published in Oncology · January 07, 2023

"The results showed numerically better median progression-free survival (PFS) outcomes compared with those observed in the MONALEESA-2 and MONALEESA-7 trials, possibly owing to more favorable baseline characteristics in the real-world cohort. The subgroup analysis revealed a trend toward longer PFS among patients with an endocrine therapy–free interval >12 months or those with de novo MBC."

"First-line ribociclib and AI combination therapy for patients with HR+/HER2− MBC is effective and safely deliverable in the real-world setting, albeit with high rates of dose reduction."